Eurofins raises EUR 296m following a successful equity issuance
Thursday, September 8, 2016
This document is not an offer of securities for sale in the United States. The shares to which this document relates have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will not be a public offering of shares in the United States.
Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, announces that it has raised total proceeds of EUR 296 million following the issuance of 800,000 new shares to institutional investors, at a price of EUR 370 per share, representing a 1.8% discount to the closing price on 7th September, 2016, and a 0.8% discount to the 1-month VWAP*.
Following strong investor demand, Eurofins’ management decided to increase the offer size from 600,000 to 800,000 new shares to secure greater funding flexibility for a potential acceleration in acquisitions. As communicated in yesterday’s press release announcing the launch of the equity offering, Eurofins intends to use proceeds from the issuance towards financing identified potential acquisition targets. These targets represent opportunities that are over and above the Group’s planned acquisition programme of EUR 200m per year to reach its revenue objective of EUR 4bn by 2020. Therefore, if completed, these acquisitions should accelerate the achievement of this objective. The objective is that they create significant value for shareholders.
Comment from Dr. Gilles Martin, Eurofins CEO: “The success of this equity issuance demonstrates investors’ confidence in our ability to deploy capital to create significant shareholder value. I would like to thank our supporters in the capital markets for the trust that they have extended over the years, and continue to give to Eurofins, and reiterate that the Board, and the executive management of Eurofins, intend to invest with the same disciplined approach that it has employed in the past, with the objective to create higher earnings per share (EPS) than the dilution impact from the new issuance.”
Berenberg and Jefferies acted as joint book-runners for the Placement. The settlement-delivery and the admission of the new shares on Euronext Paris (on the same line as Eurofins’ existing shares (ISIN code FR0000038259) should occur on the 12 of September, 2016.
*Volume Weighted Average Price
For more information, please visit www.eurofins.com or contact:
Head of Corporate Communication and Investor Relations
Eurofins Scientific SE
Phone: +32-2-769 7383
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics and discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the significant emerging players in specialty clinical diagnostic testing in Europe and the USA.
With 25,000 staff in more than 250 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.
This press release does not, and shall not, in any circumstances, constitute a public offering nor an invitation in any jurisdiction in connection with any offer.
In any Member State of the European Economic Area (“EEA”), this press release is only addressed to and directed at persons in Member States who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC, as amended).
This press release has been prepared on the basis that any offer of the new shares in any Member State of the EEA which has implemented the Prospectus Directive, and in particular in the Grand Duchy of Luxembourg and France,(each, a "Relevant Member State") will be made pursuant to an exemption under the Prospectus Directive, as implemented in that Relevant Member State, from the requirement to publish a prospectus. Accordingly any person making or intending to make any offer in that Relevant Member State of securities which are the subject of the placement contemplated in this press release may only do so in circumstances in which no obligation arises for Eurofins Scientific or any of the Joint Bookrunners to publish a prospectus pursuant to Article 3 of the Prospectus Directive, as amended, in relation to such offer. Neither Eurofins Scientific nor the Joint Bookrunners have authorized, nor do they authorize, the making of any offer of the new shares in circumstances in which an obligation arises for Eurofins Scientific or any of the Joint Bookrunners to publish prospectus for such offer.
This press release is only being distributed to, and is only directed at, persons in the United Kingdom that (i) are “investment professionals” falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This press release is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons and will be engaged in only with relevant persons.
This press release is an advertisement and not a prospectus for the purposes of applicable measures implementing Directive 2003/71/EC, as amended.
This press release is not an offer of securities for sale nor the solicitation of an offer to purchase securities in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Eurofins Scientific does not intend to register any portion of the planned offering in the United States of America or to conduct a public offering of securities in the United States of America.
It may be unlawful to distribute these materials in certain jurisdictions. These materials are not for distribution in Canada, Japan or Australia. The information in these materials does not constitute an offer of securities for sale in the United States, Canada, Japan or Australia.
Each of the Joint Bookrunners involved in the Placement is acting on behalf of Eurofins Scientific and no one else in connection with any offering of the shares and will not be responsible to any other person for providing the protections afforded to any of its clients or for providing advice in relation to any offering of Eurofins Scientific shares.
The Joint Bookrunners involved in the Placement and certain of their affiliates, have provided and may in the future provide various financing, banking, financial, investment, commercial or other services to Eurofins Scientific or to members of its group, in exchange for which they have received or may receive compensation.